September 2002 Br J Cardiol 2002;9:460-8
Iain Broom, Elixabeth Hughes, Paul Dodson, John Reckless, on behalf of the Orlistat UK Study Group
This study investigated the effect of orlistat on weight loss and serum lipid parameters in obese patients with hypercholesterolaemia. A total of 215 adult obese patients (body mass index ≥30 kg/m2) with hypercholesterolaemia (total plasma cholesterol ≥6.5 mmol/L or plasma low density lipoprotein cholesterol ≥4.2 mmol/L) were recruited for screening at 12 out-patient clinics in the UK. Of these, 142 patients were randomised to receive double-blind treatment for 24 weeks with orlistat 120 mg (n=71) or placebo (n=71) three times daily in combination with a mildly hypocaloric diet. Patients completing the double-blind phase (orlistat n=42, placebo n=55) were eligible to enter a further 28-week open-label phase and received orlistat 120 mg three times daily in combination with the hypocaloric diet.
Mean weight loss after 24 weeks was 4.4 kg (4.4%) in the orlistat group vs. 2.6 kg (2.5%) with placebo (p<0.01). At the end of the double-blind phase, 44.0% of orlistat-treated patients vs. 18.0% of placebo recipients had lost ≥5% of their initial body weight (p<0.001), and 7.6% vs. 4.2% had lost ≥10% (p=NS). Patients who continued on orlistat during the open-label phase had a mean weight loss of 4.97 kg (4.86%) after 52 weeks. Patients who switched to orlistat had a mean weight loss of 4.28 kg (4.23%). Orlistat was associated with significantly greater reductions than placebo in plasma total cholesterol (-10.88 + 1.36% vs. -3.25 + 1.33%; p<0.001) and LDL-cholesterol (-14.14 + 2.68% vs. -3.68 + 3.61%; p<0.05) during the double-blind phase. Despite similar weight loss at the end of the 52-week period, patients who remained on orlistat throughout the study had greater improvements in plasma lipid concentrations than patients who switched to orlistat after 24 weeks.
Orlistat, in combination with a mildly hypocaloric diet, promotes clinically meaningful weight loss and improvements in lipid concentrations in obese patients with hypercholesterolaemia.
September 2002 Br J Cardiol 2002;9:449-59
Sami Firoozi, Julia Rahman, William J McKenna
Hypertrophic cardiomyopathy (HCM) is the commonest inherited cardiovascular disorder with a prevalence of one in 500 in the general population. It is believed to be a disease of the cardiac sarcomere and is caused by a variety of mutations in genes responsible for sarcomeric contractile proteins. It is characterised macroscopically by myocardial hypertrophy and microscopically by myocyte fibrosis and disarray. Most patients tend to present with functional limitation and symptoms such as palpitation, chest pain or syncope. The underlying mechanisms involved are complex, multiple and not yet fully understood. Further clarification of these mechanisms may enable improvements in current symptom control or the development of new avenues of therapy. A small but significant proportion of patients suffer sudden cardiac death and this can be the initial presentation of the condition. In fact, HCM is the commonest cause of sudden death among individuals below the age of 30 years. The identification of this high-risk cohort remains the most important aspect of HCM management, particularly in light of growing evidence of the effectiveness of prophylactic strategies.
September 2002 Br J Cardiol (Acute Interv Cardiol) 2002;9(1):AIC 5–AIC 10
The implications of the Secretary of State’s approval of the introduction of league tables for cardiac surgeons are discussed. Surgeons are to be ranked according to mortality rates for first-time coronary artery bypass graft operations. It is questionable whether anybody will gain from this information: the focus of surgeons’ attention is transferred from patient care to self-preservation. The introduction of league tables in New York State has resulted in surgeons being reluctant to operate on higher risk patients and in secondary referrals of patients out of the State. League tables also encourage the manipulation of risk factor status.
Many factors other than the individual surgeon’s skill influence the quality of care and patient outcomes. These factors include the patient’s status, the timing of surgery, the surgical team, equipment in the operating room and post-operative care.
An alternative to the punitive process of public reporting is the application of continuous quality improvement to healthcare. This starts from the position that most negative outcomes are due not to individual failures but to failures of process and systems.
September 2002 Br J Cardiol (Acute Interv Cardiol) 2002;9(1):AIC 13–AIC 17
Marios Tryfonidis, Brian Prendergast, Nicholas Curzen
The objective of this study was to test the hypothesis that some patients on the routine waiting list for coronary artery bypass (CABG) surgery are suitable for percutaneous coronary intervention (PCI), as suggested in the NICE appraisal of coronary artery stents. A retrospective analysis was performed of 100 consecutive patients who had recently undergone CABG surgery from the routine waiting list in a tertiary cardiothoracic centre. The coronary angiograms of these patients were reviewed by an interventional cardiologist and a cardiac surgeon to assess patients’ potential suitability for PCI.
The mean total waiting time from being listed for angiography to having CABG surgery was 18.7 months. The mean delay from angiography to CABG surgery was 13.5 months. Of the 100-patient cohort, 70 were referred by a non-interventional cardiologist and 30 by an interventionalist (ratio 2.3:1). Fifteen patients were deemed potentially suitable for PCI after angiographic review. Of these, 13 (87%) were referred by a non-interventional cardiologist without angiographic review by an interventional specialist. The majority (86%) of the 15 patients deemed potentially suitable for PCI had single or double vessel coronary artery disease, in contrast to the population as a whole (38%).
These data suggest (a) that current CABG waiting lists could be reduced by up to 15% if coronary angiograms were reviewed by an interventional cardiologist in addition to a consultant cardiothoracic surgeon and (b) that referral arrangements should be adopted to facilitate such a review. The clinical implications of these data could be fully assessed by rolling out prospectively to other groups in the Coronary Heart Disease Collaborative.
September 2002 Br J Cardiol (Acute Interv Cardiol) 2002;9(1):AIC 20–AIC 25
Tushar V Saluhke, Duncan LA Wyncoll
Critically ill patients in the coronary care or high dependency units (CCU, HDU) need accurate assessment of their haemodynamic status to guide fluid or vasoactive drug therapy. Both central venous pressure and pulmonary artery occlusion pressure are poor guides to cardiac filling and pulmonary oedema, and using a pulmonary artery catheter often fails to improve clinical outcome.
The PiCCO system is a relatively new and less invasive approach to cardiac monitoring. It has been used extensively in intensive care and is reviewed in this article. This approach uses thermo-dilution techniques to reliably calculate volumetric measurements of cardiac preload and cardiac output, and can provide continuous real-time cardiac output and stroke volume variation measurements through pulse contour analysis. The reliability and accuracy of this method has drastically refined fluid and vasopressor management of the hypotensive patient and the management and prevention of pulmonary oedema. This method of measuring cardiac output correlates well with gold standard methods of cardiac output calculation and has been validated in adults and children.
The PiCCO system can be an invaluable tool in the optimisation of the circulation in cardiac, medical and surgical patients commonly seen in the CCU and HDU.
September 2002 Br J Cardiol (Acute Interv Cardiol) 2002;9(1):AIC 26–AIC 31
Liam J Cormican, A Craig Davidson
Chronic heart failure is a progressive syndrome which continues to have high rates of morbidity and mortality. Heart failure rates are increasing in parallel with the ageing population, as are rates of hospitalisation for acute episodes of decompensated failure. Little progress has been made in the medical management of such episodes. Positive inotropes, including selective phosphodiesterase III inhibitors, are associated with increased mortality when administered over the long term. Now newer approaches, using selective agents such as enoximone orally at lower doses alone or in combination with carefully titrated beta1-selective adrenergic blockade, may provide a more favourable outcome in terms of symptom management, functional status and improved survival. Trials are underway to determine whether this is the case. Published trials with enoximone and protocols for forthcoming trials are reviewed.
August 2002 Br J Cardiol 2002;9:
BJCardio editorial team
THE CHOLESTEROL MANAGEMENT DEBATES ESC debate Motion 1: “This house believes that lowering current cholesterol targets will have additional benefits to CV risk management” Motion 2: “This house believes that the benefits of raising HDL warrant its introduction as another lipid variable to target.” The lower the better. The real benefits of lowering cholesterol even further The Atlantic divide in coronary prevention PCCS debate Motion 1: “This house believes that current government policy is leading to the erosion of clinical judgement, exemplified by the CHD National Service Framework.” Motion 2: “This house believes that optimal management of cholesterol is a relief, not a burden.” The National Service Framework for CHD – Big Brother or helpful guide? A stitch in time – counting the cost of optimal CHD prevention
July 2002 Br J Cardiol 2002;9:422-4
The proportion of the elderly population is rapidly growing, increasing the numbers of hypertensive patients and the workload in primary care. The average GP will currently have around 100 hypertensive patients over the age of 75 years in their care; this number is likely to be much higher in popular retirement areas. Clinical trials have shown the benefits of vigorous blood pressure control in the elderly; current recommendations are to reduce blood pressure to under 140/85 mmHg in at-risk groups and to under 130/80 mmHg in diabetics. Hypertension treatment continues to be difficult, however, due to poor compliance. This is for a number of reasons, including the fact that it is often a symptomless condition, the side effects of antihypertensive medication and the number of concomitant medical conditions making drug regimes complicated in the elderly. Newer classes of antihypertensive agents, such as beta blockers, angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists, are proving to reduce other risks as well as reducing blood pressure. Angiotensin II receptor antagonists appear to be better tolerated than other antihypertensive drugs; clinical trial results are awaited to assess their protective effects as well as their effect on quality of life, health economics and cost-effectiveness.
July 2002 Br J Cardiol 2002;9:411-3
Duncan Hogg, Stephen Yule, Kevin Jennings
We describe an asymptomatic 51-year-old man in whom severe coronary artery ectasia was evident on a plain AP chest X-ray (CXR).
July 2002 Br J Cardiol 2002;9:406-10
Badri Chandrasekaran, Arvinder S Kurbaan
Brugada syndrome was described 10 years ago. It is a syndrome of sudden cardiac death associated with partial right bundle branch block and ST segment elevation in the right precordial leads V1-V3 on the resting ECG. Those affected have structurally normal hearts (as demonstrated by standard techniques) but they have a mortality rate of 10% a year, whether they are symptomatic or asymptomatic. It is thought to be primarily a disease of cardiac conduction and has been linked to abnormalities in the sodium channel (SCN5A). Differential diagnoses include arrhythmogenic right ventricular dysplasia, idiopathic ventricular fibrillation and polymorphic ventricular tachycardia. Brugada et al. suggest that the Brugada shift pattern on 12-lead ECG is a specific marker for those at risk of sudden death. They recommend that symptomatic individuals be protected with an implantable cardiac defibrillator. Asymptomatic individuals remain a diagnostic dilemma.